http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 16:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Aug+06/26890794.html si-local-file:///var/storage/secattach/20260807/26890794.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Aug+06/26890794.html Fri, 07 Aug 2026 16:00:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Aug+06/26890794.html si-local-file:///var/storage/secattach/20260807/26890794.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Aug+06/26890794.html Fri, 07 Aug 2026 16:00:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Apyx+Medical+Corp+++++++++For%3A+Jun+30/26885353.html si-local-file:///var/storage/secattach/20260806/26885353.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Apyx+Medical+Corp+++++++++For%3A+Jun+30/26885353.html Thu, 06 Aug 2026 17:02:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Apyx+Medical+Corp+++++++++For%3A+Jun+30/26885353.html si-local-file:///var/storage/secattach/20260806/26885353.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Apyx+Medical+Corp+++++++++For%3A+Jun+30/26885353.html Thu, 06 Aug 2026 17:02:00 -0400 APYX O.00062975 http://www.streetinsider.com/Earnings/Apyx+Medical+Corp.+%28APYX%29+Tops+Q2+EPS+by+2c+%3B+Offers+Guidance/26883809.html <p>Apyx Medical Corp. (NASDAQ: APYX) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $13.32 million.</p><p><strong>GUIDANCE:</strong></p><p>Apyx Medical Corp. sees FY2026 revenue of $59-60 million, versus the consensus of $59.55 million.</p><p>For earnings history and earnings-related data on Apyx Medical Corp. (APYX) <a href="http://www.streetinsider.com/ec_earnings.php?q=APYX">click here</a>.</p> http://www.streetinsider.com/Earnings/Apyx+Medical+Corp.+%28APYX%29+Tops+Q2+EPS+by+2c+%3B+Offers+Guidance/26883809.html Thu, 06 Aug 2026 16:10:45 -0400 APYX http://www.streetinsider.com/Guidance/Apyx+Medical+Corp.+%28APYX%29+Tops+Q2+EPS+by+2c+%3B+Offers+Guidance/26883809.html <p>Apyx Medical Corp. (NASDAQ: APYX) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $13.32 million.</p><p><strong>GUIDANCE:</strong></p><p>Apyx Medical Corp. sees FY2026 revenue of $59-60 million, versus the consensus of $59.55 million.</p><p>For earnings history and earnings-related data on Apyx Medical Corp. (APYX) <a href="http://www.streetinsider.com/ec_earnings.php?q=APYX">click here</a>.</p> http://www.streetinsider.com/Guidance/Apyx+Medical+Corp.+%28APYX%29+Tops+Q2+EPS+by+2c+%3B+Offers+Guidance/26883809.html Thu, 06 Aug 2026 16:10:45 -0400 APYX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Aug+06/26883901.html si-local-file:///var/storage/secattach/20260806/26883901.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Aug+06/26883901.html Thu, 06 Aug 2026 16:10:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Aug+06/26883901.html si-local-file:///var/storage/secattach/20260806/26883901.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Aug+06/26883901.html Thu, 06 Aug 2026 16:10:00 -0400 APYX O.00062975 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html <ul type="disc"><li style="text-align:justify;"><em>Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment</em></li><li style="text-align:justify;"><em>Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026</em></li><li style="text-align:justify;"><em>Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million</em></li><li style="text-align:justify;"><em>Management to host a conference call today at 4:30 p.m. ET </em></li></ul> <p align="justify">CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx</strong> <strong>Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html Thu, 06 Aug 2026 16:05:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html <ul type="disc"><li style="text-align:justify;"><em>Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment</em></li><li style="text-align:justify;"><em>Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026</em></li><li style="text-align:justify;"><em>Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million</em></li><li style="text-align:justify;"><em>Management to host a conference call today at 4:30 p.m. ET </em></li></ul> <p align="justify">CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx</strong> <strong>Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html Thu, 06 Aug 2026 16:05:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html <ul type="disc"><li style="text-align:justify;"><em>Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment</em></li><li style="text-align:justify;"><em>Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026</em></li><li style="text-align:justify;"><em>Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million</em></li><li style="text-align:justify;"><em>Management to host a conference call today at 4:30 p.m. ET </em></li></ul> <p align="justify">CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx</strong> <strong>Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html Thu, 06 Aug 2026 16:05:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html <ul type="disc"><li style="text-align:justify;"><em>Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment</em></li><li style="text-align:justify;"><em>Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026</em></li><li style="text-align:justify;"><em>Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million</em></li><li style="text-align:justify;"><em>Management to host a conference call today at 4:30 p.m. ET </em></li></ul> <p align="justify">CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx</strong> <strong>Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html Thu, 06 Aug 2026 16:05:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html <ul type="disc"><li style="text-align:justify;"><em>Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment</em></li><li style="text-align:justify;"><em>Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026</em></li><li style="text-align:justify;"><em>Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million</em></li><li style="text-align:justify;"><em>Management to host a conference call today at 4:30 p.m. ET </em></li></ul> <p align="justify">CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx</strong> <strong>Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html Thu, 06 Aug 2026 16:05:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html <ul type="disc"><li style="text-align:justify;"><em>Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment</em></li><li style="text-align:justify;"><em>Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026</em></li><li style="text-align:justify;"><em>Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million</em></li><li style="text-align:justify;"><em>Management to host a conference call today at 4:30 p.m. ET </em></li></ul> <p align="justify">CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx</strong> <strong>Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html Thu, 06 Aug 2026 16:05:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html <ul type="disc"><li style="text-align:justify;"><em>Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment</em></li><li style="text-align:justify;"><em>Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026</em></li><li style="text-align:justify;"><em>Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million</em></li><li style="text-align:justify;"><em>Management to host a conference call today at 4:30 p.m. ET </em></li></ul> <p align="justify">CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx</strong> <strong>Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html Thu, 06 Aug 2026 16:05:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html <ul type="disc"><li style="text-align:justify;"><em>Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment</em></li><li style="text-align:justify;"><em>Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026</em></li><li style="text-align:justify;"><em>Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million</em></li><li style="text-align:justify;"><em>Management to host a conference call today at 4:30 p.m. ET </em></li></ul> <p align="justify">CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx</strong> <strong>Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results/26883585.html Thu, 06 Aug 2026 16:05:00 -0400 A.50216777 APYX O.00062975 O.54516537 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26822632.html <p align="justify">CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.</p> <p align="justify">Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 11, 2026, at 2:30pm ET and will hold one-on-one meetings with investors throughout the http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26822632.html Tue, 28 Jul 2026 08:00:00 -0400 APYX O.00062975 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26822632.html <p align="justify">CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.</p> <p align="justify">Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 11, 2026, at 2:30pm ET and will hold one-on-one meetings with investors throughout the http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26822632.html Tue, 28 Jul 2026 08:00:00 -0400 APYX O.00062975 http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26822632.html <p align="justify">CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.</p> <p align="justify">Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 11, 2026, at 2:30pm ET and will hold one-on-one meetings with investors throughout the http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26822632.html Tue, 28 Jul 2026 08:00:00 -0400 APYX O.00062975 http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26822632.html <p align="justify">CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.</p> <p align="justify">Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 11, 2026, at 2:30pm ET and will hold one-on-one meetings with investors throughout the http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26822632.html Tue, 28 Jul 2026 08:00:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Jul+24/26814354.html si-local-file:///var/storage/secattach/20260724/26814354.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Jul+24/26814354.html Fri, 24 Jul 2026 17:18:00 -0400 APYX O.00062975 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Jul+24/26814354.html si-local-file:///var/storage/secattach/20260724/26814354.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Apyx+Medical+Corp+++++++++For%3A+Jul+24/26814354.html Fri, 24 Jul 2026 17:18:00 -0400 APYX O.00062975 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+to+Release+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+6%2C+2026/26804880.html <p>CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the second quarter of fiscal year 2026 will be released after markets close on Thursday, August 6th.</p> <p>Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 6th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+to+Release+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+6%2C+2026/26804880.html Thu, 23 Jul 2026 08:00:00 -0400 APYX O.00062975 http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+to+Release+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+6%2C+2026/26804880.html <p>CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the second quarter of fiscal year 2026 will be released after markets close on Thursday, August 6th.</p> <p>Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 6th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or http://www.streetinsider.com/Press+Releases/Apyx+Medical+Corporation+to+Release+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+6%2C+2026/26804880.html Thu, 23 Jul 2026 08:00:00 -0400 APYX O.00062975 http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+to+Release+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+6%2C+2026/26804880.html <p>CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the second quarter of fiscal year 2026 will be released after markets close on Thursday, August 6th.</p> <p>Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 6th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or http://www.streetinsider.com/Globe+Newswire/Apyx+Medical+Corporation+to+Release+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+6%2C+2026/26804880.html Thu, 23 Jul 2026 08:00:00 -0400 APYX O.00062975